Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129)

NCT00550615 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT00550615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00550615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129)
Lead sponsor
University of Nebraska
Phase
Phase 1/2
Overall status
Completed
Start date
September 17, 2007
Completion date
December 1, 2017
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma